Table 1.

Clinical outcome of peptide vaccine for advanced solid cancer

Protocol	Cancer	HLA restriction	No. vaccinated peptides	Total no. patients	Best clinical response by RECIST			Reference
					PR	SD	PD
Classical (non‐personalized)
	Lung	HLA‐A24	2	11	0	2	9	6
	Stomach	HLA‐A24, ‐A2	4	8	0	4	4	27
	Colorectal	HLA‐A24	2	12	0	1	11	19
	Uterine (cervix)	HLA‐A24, ‐A2	2–4	7	0	2	5	9, 27
	Total			38	0	9	29
Personalized	Lung	HLA‐A24, ‐A2	4 †	10	0	7	3	8
	Stomach	HLA‐A24	4 †	11	0	5	6	12
	Colorectal	HLA‐A24, ‐A2	4 †	10	1	1	8	22
	Pancreas	HLA‐A24, ‐A2	4 †	9	0	3	6	23
	Uterine (Cervix)	HLA‐A24, ‐A2	4†	4	2	1	1	9
	Skin (melanoma)	HLA‐A24	4†	7	0	3	4	24
	Brain (grade 3/4)	HLA‐A24	4 ‡	21	5	8	8	10
	Total			72	8	28	36

^† Pre‐vaccination peripheral blood mononuclear cells (PBMC) were provided to examine cellular immune responses to 14 or 16 peptide panels in HLA‐A24⁺ or HLA‐A2⁺ patients, respectively. The positively identified peptides (up to four per patient) were subsequently chosen for vaccination.

^‡ Pre‐vaccination PBMC and plasma were provided to examine cellular and humoral immune responses to 25 or 23 peptide panels in HLA‐A24⁺ or HLA‐A2⁺ patients, respectively. The positively identified peptides (up to four per patient) were subsequently chosen for vaccination. HLA, Human Leukocyte antigen; PD, progressive disease; PR, partial response; RECIST, response evaluation criteria in solid tumors; SD, stable disease.